CISD3

Across TCGA pan-cancer cohorts, CISD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CISD3 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CISD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CISD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where CISD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.606	0.957	.002	24	view →
PDAC	DFS	Median	All	0.828	0.618	.001	18	view →
HNSC	OS	Median	All	1.000	0.484	.038	12	view →
LSCC	DFS	Tertile	All	1.000	0.912	.021	10	view →
LUAD	OS	Tertile	III,IV	0.993	0.534	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CISD3–CCRCC (DFS)

Open the CCRCC breakdown →